Amitiza (Lubiprostone)

Similar documents
Methylnaltrexone Bromide (Relistor)

Texas Prior Authorization Program Clinical Edit Criteria

Texas Prior Authorization Program Clinical Criteria

Sitagliptin (Januvia)

Texas Prior Authorization Program Clinical Edit Criteria

Texas Prior Authorization Program Clinical Criteria

Texas Prior Authorization Program Clinical Edit Criteria

Diclofenac 3% Gel, Diclofenac 1.5% and 2% Topical Solution

Hypoglycemics, Lantus Insulin

Texas Prior Authorization Program Clinical Edit Criteria

Lidoderm (Lidocaine) Patch

Agents for the Treatment of Hepatitis C

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

Victoza (Liraglutide) Solution for Injection

Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH)

Prior Authorization Neurontin (gabapentin) 2016

Texas Prior Authorization Program Clinical Edit Criteria

Texas Prior Authorization Program Clinical Criteria. This criteria was recommended for review by an MCO to ensure appropriate and safe utilization.

Texas Prior Authorization Program Clinical Criteria

Flexeril/Amrix (Cyclobenzaprine)

Amitiza. Amitiza (lubiprostone) Description

Texas Prior Authorization Program Clinical Edit Criteria

Byetta (Exenatide Injection)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents

Agents for Cystic Fibrosis

Texas Prior Authorization Program Clinical Criteria. Allergen Extracts

Texas Prior Authorization Program Clinical Edit Criteria. H.P. Acthar

Fentanyl Agents Clinical Edit Criteria

DOCTOR DISCUSSION GUIDE

Texas Prior Authorization Program Clinical Edit Criteria

Flexeril/Amrix (Cyclobenzaprine) Clinical Edit Criteria

Texas Prior Authorization Program Clinical Edit Criteria

Drug Regimen Optimization

Prior Authorization Flexeril/Amrix (cyclobenzaprine) 2017

Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria

Movantik (naloxegol), Relistor (methylnaltrexone bromide), Symproic (naldemedine)

Texas Prior Authorization Program Clinical Edit Criteria

Texas Prior Authorization Program Clinical Edit Criteria

Cystic Fibrosis Agents

Cystic Fibrosis Agents

Movantik (naloxegol), Relistor (methylnaltrexone bromide)

Texas Prior Authorization Program Clinical Criteria

Drug Regimen Optimization

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 2Q17 April May

daily; available as 10- mg g PO

Viberzi. Viberzi (eluxadoline) Description

Dextromethorphan Overutilization

Movantik (naloxegol), Relistor (methylnaltrexone bromide), Symproic (naldemedine)

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria

Morphine Sulfate Hydromorphone Oxymorphone

Treatment Conversation Guide

Xyrem (Sodium Oxybate)

Texas Prior Authorization Program Clinical Edit Criteria

Prior Authorization Opioid Overutilization 2017

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August

FULL PRESCRIBING INFORMATION: CONTENTS*

Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation

Texas Prior Authorization Program Clinical Edit Criteria

Cough/Cold Medications

Viberzi. Viberzi (eluxadoline) Description

General Surgery Curriculum Royal Australasian College of Surgeons, General Surgeons Australia & New Zealand Association of General Surgeons

GA KS KY LA MD NJ NV NY TN TX WA Applicable X X N/A N/A X N/A X X X X X X N/A N/A NA *FHK- Florida Healthy Kids. Androgens

Opioid-Induced Constipation

OPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES

Nursing diagnosis for diverticular disease

See Important Reminder at the end of this policy for important regulatory and legal information.

Reference ID:

GI Coding Updates. Rhonda Buckholtz, CPC, CPCI, CPMS, CRC, CDEO, CHPSE, CGSC, COBGC, CENTC, CPEDC

PACKAGE LEAFLET: INFORMATION FOR THE USER AMITIZA 24 MICROGRAM SOFT CAPSULES. Lubiprostone

AMITIZA (lubiprostone) capsules, for oral use Initial U.S. Approval: 2006

In this edition we will take a look at Cholelithiasis diagnoses and illustrate the increased specificity under the ICD-10-CM nomenclature.

Is one of the most common chronic disorders. causing patients to seek medical treatment.

What GI Physicians Need to Know About Probiotics

Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy

Texas Vendor Drug Program. Drug Use Criteria: Hydrocodone Bitartrate/ Hydrocodone Polistirex. Publication History

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Duragesic patch. Duragesic patch (fentanyl patch) Description

Colonic pseudo obstruction icd 10

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

ICD-10 Common Codes for Pelvic Rehab Providers

AMITIZA (lubiprostone) capsules, for oral use Initial U.S. Approval: 2006

Total Parenteral Nutrition and Enteral Nutrition in the Home. Original Policy Date 12:2013

Gattex. Gattex (teduglutide) Description

Irritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM

1.* Dosage/Administration

Efficacy and Safety of Lubiprostone. Laura Wozniak February 23, 2010 K30 Monthly Journal Club

GI Coding Updates. Rhonda Buckholtz, CPC, CPCI, CPMS, CRC, CDEO, CHPSE, CGSC, COBGC, CENTC, CPEDC

Small-Bowel and colon Transit. Mahsa Sh.Nezami October 2016

Icd 10 code for failed back surgery syndrome lumbar

Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy

Summary of risk management plan for Dzuveo (Sufentanil (as citrate))

REFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

(linzess) for irritable Bowel syndrome With Constipation and For Chronic idiopathic Constipation

Sildenafil / Tadalafil

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Transcription:

Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical edit Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical edit criteria rules Logic diagram: a visual depiction of the clinical edit criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes) References: clinical publications and sources relevant to this clinical edit te: Click the hyperlink to navigate directly to that section. Revision tes Revised step 4 of clinical edit criteria logic to include diagnosis of chronic idiopathic constipation or opioid-induced constipation with chronic, noncancer pain May 24, 2013 Copyright 2012-2013 Health Information Designs, LLC 1

Drugs Requiring Prior Authorization Drugs Requiring Prior Authorization Label Name GCN AMITIZA (LUBIPROSTONE) 8 MCG 99658 AMITIZA (LUBIPROSTONE) 24MCG 26473 CAPSULES May 24, 2013 Copyright 2012-2013 Health Information Designs, LLC 2

Clinical Edit Criteria Logic 1. Is the client greater than or equal to ( ) 18 years of age? [ ] (Go to #2) [ ] (Deny) 2. Does the client have a diagnosis of irritable bowel syndrome in the last 365 days? [ ] (Go to #3) [ ] (Go to #4) 3. Is the client a female? [ ] (Go to #5) [ ] (Deny) 4. Does the client have a diagnosis of chronic idiopathic constipation or opioidinduced constipation with chronic, non-cancer pain in the last 365 days? [ ] (Go to #5) [ ] (Deny) 5. Does the client have a history of a GI obstruction in the last 730 days? [ ] (Deny) [ ] (Go to #6) 6. Does the client have a history of lubiprostone in the past 45 days? [ ] (Approve 365 days) [ ] (Go to #7) 7. Is the quantity being requested less than or equal to ( ) 2 caps/day? [ ] (Approve 365 days) [ ] (Deny) May 24, 2013 Copyright 2012-2013 Health Information Designs, LLC 3

Clinical Edit Criteria Logic Diagram Step 4 Step 1 Is the client 18 years of age? Step 2 Does the client have a diagnosis of irritable bowel syndrome in the last 365 days? Does the client have a diagnosis of chronic idiopathic constipation or opioid-induced constipation with chronic, non-cancer pain in the last 365 days? Deny Request Step 3 Step 5 Deny Request Is the client a female? Does the client have a history of a GI obstruction in the last 730 days? Deny Request Deny Request Step 7 Is the quantity being requested to 2 caps/day? Step 6 Does the client have a history of lubiprostone in the past 45 days? Approve Request (365 days) Approve Request (365 days) May 24, 2013 Copyright 2012-2013 Health Information Designs, LLC 4

Clinical Edit Criteria Supporting Tables Step 2 (diagnosis of irritable bowel syndrome) Required quantity: 1 Look back timeframe: 365 days ICD-9 Code Description 5641 IRRITABLE BOWEL SYNDROME Step 4 (diagnosis of constipation) Required diagnosis: 1 Look back timeframe: 365 days ICD-9 Code Description 5640 CONSTIPATION 56400 CONSTIPATION, UNSPECIFIED 56401 SLOW TRANSIT CONSTIPATION 56402 OUTLET DYSFUNCTION CONSTIPATION Step 5 (history of GI obstruction) Required quantity: 1 Look back timeframe: 730 days ICD-9 Code Description 5600 INTUSSUSCEPTION 5601 PARALYTIC ILEUS 5602 VOLVULUS OF INTESTINE 56031 GALLSTONE ILEUS 56081 INTESTINAL ADHES W OBSTR 56089 INTESTINAL OBSTRUCT NEC 5609 INTESTINAL OBSTRUCT NOS May 24, 2013 Copyright 2012-2013 Health Information Designs, LLC 5

Step 6 (history of lubiprostone) Required quantity: 1 Look back timeframe: 45 days Label Name AMITIZA (LUBIPROSTONE) 8MCG CAPSULES AMITIZA (LUBIPROSTONE) 24MCG CAPSULES GCN 99658 26473 May 24, 2013 Copyright 2012-2013 Health Information Designs, LLC 6

Clinical Edit Criteria References 1. Amitiza [package insert]. Deerfield, IL: Takeda Pharmaceuticals rth America. Available at http://www.amitiza.com/. Accessed on July 7, 2011. 2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc., updated January 2011. Available at http://www.clinicalpharmacology.com/?epm=2_1. 3. 2011 ICD-9-CM Diagnosis Codes, Volume 1, 2011. Available at http://www.icd9data.com/. Accessed on August 14, 2011. May 24, 2013 Copyright 2012-2013 Health Information Designs, LLC 7

Publication History The Publication History records the publication iterations and revisions to this document. Publication Date tes 04/12/2012 Initial publication and posting to website 05/24/2013 Revised step 4 to include diagnosis of chronic idiopathic constipation or opioid-induced constipation with chronic, non-cancer pain May 24, 2013 Copyright 2012-2013 Health Information Designs, LLC 8